This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.

Eligible subjects will receive open-label AXS-07 for up to 8 weeks for at-home treatment of their next 4 migraine attacks.

Inclusion Criteria:

• Has an established diagnosis of migraine with or without aura
• Has experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine

Exclusion Criteria:

• Pregnant, breastfeeding, or planning to become pregnant during the study
• Has previously received any investigational drug or device or investigational therapy within 30 days before Screening